Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:35:30 EDT Tue 18 Aug 2026
Enter Symbol
or Name
USA
CA



Q:CORT - CORCEPT THERAPEUTICS INC - https://www.corcept.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CORT - Q1.0118.56·121.873.0118.10+0.930.8803.994,34312,780116.595  119.95  116.595122.205  28.660119:48:25Jul 2915 min RT 2¢

Recent Trades - Last 10 of 12780
Time ETExPriceChangeVolume
19:48:25Q119.99992.829999
19:38:37Q118.551.3824
19:34:09Q118.511.341
19:34:07Q118.511.341
18:47:32Q119.40952.23951
18:45:02Q120.002.8350
17:56:59Q118.110.949
17:38:13Q118.110.9410
17:14:24Q118.100.931
17:06:06Q117.00-0.1734

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-07-29 16:05U:CORTNews ReleaseCorcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
2026-07-22 16:05U:CORTNews ReleaseCorcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
2026-06-17 16:28U:CORTNews ReleaseCorcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome
2026-06-06 16:45U:CORTNews ReleaseCorcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym(TM)
2026-05-29 16:33U:CORTNews ReleaseCorcept Presents New Data at ASCO 2026: Lifyorli(TM) Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
2026-05-27 08:00U:CORTNews ReleaseCorcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome
2026-04-30 16:05U:CORTNews ReleaseCorcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
2026-04-30 16:05U:CORTNews ReleaseCorcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
2026-04-23 16:05U:CORTNews ReleaseCorcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
2026-04-21 13:09U:CORTNews ReleaseCorcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli(TM) (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026
2026-04-10 16:45U:CORTNews ReleaseCorcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli(TM) (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
2026-03-28 14:45U:CORTNews ReleaseCorcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session
2026-03-25 12:43U:CORTNews ReleaseFDA Approves Corcept's Selective Glucocorticoid Receptor Antagonist Lifyorli(TM) (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer
2026-02-24 16:05U:CORTNews ReleaseCorcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update
2026-02-19 16:00U:CORTNews ReleaseCorcept Provides Update on Patent Dispute with Teva Pharmaceuticals
2026-02-17 16:05U:CORTNews ReleaseCorcept Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results, Provide Corporate Update and Host Conference Call
2026-01-22 08:00U:CORTNews ReleaseOverall Survival Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
2025-12-31 08:00U:CORTNews ReleaseCorcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism
2025-11-04 16:05U:CORTNews ReleaseCorcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update
2025-10-28 16:05U:CORTNews ReleaseCorcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call